Elevation Oncology, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
SCHEDULE: BML Investment Partners Reports 0% Stake in Elevation Oncology Following Tender Offer Completion
BML Investment Partners, L.P. has filed an amended Schedule 13D, indicating zero beneficial ownership of Elevation Oncology, Inc. common stock after the completion of a tender offer for all outstanding shares.
SCHEDULE 13D: Activist Investor BML Capital Pushes Elevation Oncology for Immediate Liquidation and Shareholder Cash Return
BML Investment Partners, holding a 9.9% stake in Elevation Oncology, has formally urged the company's Board of Directors to pursue an orderly winddown, liquidation, and return of capital to shareholders, citing unfavorable market conditions and poor performance of recent biopharma reverse mergers.